Xenon Pharmaceuticals Inc (XENE) オプション

Epilepsy 
Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. We are currently developing azetukalner for the treatment of epilepsy, including focal onset seizures, or FOS, and primary generalized tonic-clonic seizures, or PGTCS, as well as major depressive disorder, or MDD, while exploring applicability in other neuropsychiatric disorders.

Epilepsy Programs

•
Phase 3 FOS studies continue to advance, with the first topline data readout from X-TOLE2 anticipated in the second half of 2025. The Phase 3 FOS clinical trials are multicenter, randomized, double-blind, placebo-controlled studies evaluating the clinical efficacy, safety, and tolerability of azetukalner in patients with FOS. 
•
Phase 3 X-ACKT clinical study is currently enrolling patients and is intended to support potential regulatory submissions in an additional epilepsy indication of PGTCS. This multicenter, randomized, double-blind, placebo-controlled trial is evaluating the clinical efficacy, safety and tolerability of azetukalner in patients with PGTCS. 
•
Building upon the 600 patient-years of drug exposure to date, we continue to generate long-term scientific evidence demonstrating azetukalner’s compelling efficacy and safety profile in the ongoing X-TOLE open-label extension, or OLE, study.

XENE rangebound

XENE new 52 week high

MEAN XENE @ it aGAIN

I bought some yesterday at close (26) hopefully I didn’t buy too high I never really buy while it’s up that much

$34 CLOSE= WOW


even after the Offering


XENE on radars))))))) tomorrow

Don't really care about the semantics just the trade. Already up 1,000 on my Call

$XENE Has $3.5M in debt

oh it will :D

WOW the $250M offering didnt really affect the pps


pretty impressive

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $250 million of its common shares pursuant to its existing shelf registration statement. It is expected that the underwriters of the offering will be granted an option for a period of 30 days to purchase up to an additional $37.5 million of common shares at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

Offering —> Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a clinical stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of $250 million of its common shares pursuant to its existing shelf registration statement. It is expected that the underwriters of the offering will be granted an option for a period of 30 days to purchase up to an additional $37.5 million of common shares at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

offering after hrs

$33'S WOW

XENE


I let my 6200 go too early

If it breaks 30 it's gonna pop

Let's run the 30's >

YEHHHAAAAAAAA!

$30.47 new highs

XENE

William Blair Raises Price Target From $30 To $46; Raises Probability Of Success For XEN1101 In FOS From 60% To 85%

XENE

500 shares to see where it goes

37M trading float >

XENE

MEAN XENE

Not the flyest numbers. -83.4% Rev growth, -334.68% Operating margin

Profitability
Profit Margin 0.00%
Operating Margin (ttm) -334.68%

Management Effectiveness
Return on Assets (ttm) -15.76%
Return on Equity (ttm) -26.46%

Income Statement
Revenue (ttm) 18.28M
Revenue Per Share (ttm) 0.48
Quarterly Revenue Growth (yoy) -83.40%
Gross Profit (ttm) -18.36M
EBITDA -60.38M
Net Income Avi to Common (ttm) -57.5M

Good news but only phase 2. A long way to go still and will cost a lot of money to get there. Hemorrhaging almost $100,000,000 a hundred million a quarter.

Cash Flow Statement
Operating Cash Flow (ttm) -58.05M
Levered Free Cash Flow (ttm) -40.73M

30.24

Xenon Pharmaceuticals Reports Positive Phase 2b Result for Epilepsy Drug
7:21 am ET October 4, 2021 (Dow Jones) Print

By Matt Grossman


Xenon Pharmaceuticals Inc.'s XEN1101 drug achieved positive results in a Phase 2b trial studying its use as an adjunctive treatment for focal epilepsy, the company said Monday.

Compared with a placebo, the drug achieved a statistically significant reduction from the baseline in monthly focal seizure frequency, meeting the study's primary efficacy endpoint.

More than half of patients who received the highest dose of the medication studied experienced a greater-than-50% reduction in seizure frequency, Xenon said. At the median, participants had been experiencing a baseline level of 13.5 seizures per month before the study.

Xenon Chief Executive Ian Mortimer said that the results support an "attractive clinical profile" for the drug. Data from the study have also encouraged Xenon's plans to additionally develop the drug for the treatment of major depressive disorder and for other types of epilepsy, he said.


Write to Matt Grossman at matt.grossman@wsj.com


(END) Dow Jones Newswires

October 04, 2021 07:21 ET (11:21 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

XENE

Insider trade alert, but low volumes

On watch

I mean I think you could play today for a quick rebound and flip it. I picked up 1k shares @4.80. See what happens. GL.

$3.50-$3.75 should be a nice area to get shares imo for a nice flip?

Xenon (NASDAQ:XENE) has bucked the downward trend in biotech this month and is up some 10% over the past few weeks. The stock also managed to rise nicely Friday even as the overall biotech sector gave up Thursday's gains. It sells for almost the exact price of Omeros as of the close of the trading week.
Since early August, three analyst firms have reiterated or initiated Buy ratings on this small biotech concern based in Canada. Price targets proffered range from $13 to $20 a share. Guggenheim is the most optimistic on Xenon with a $20 price target. Its analyst noted three reasons to be positive on the firm.
"1. XEN801 addresses an unmet need within the, large, ~$3.7B acne market and could present a novel mechanism of action to treat acne. The three mechanisms of action most commonly used to treat acne have been available for over 30 years. That said, innovative therapies launched over the past few decades have resulted in significant sales. This gives us confidence that XEN801 sales could exceed consensus expectations if it is approved.
2. The pain market needs safer drugs, outside of opioids, which XENE's Nav1.7 blockers could address. The government and the FDA's desire to reduce the abuse of opioids supports the development of novel pain drugs such as XENE's Nav1.7 blockers. We believe XENE and its partners for these drugs are well positioned to benefit from initiatives to move the market away from opioids.
3. There is a free call option on XENE's approved drug, Glybera, and other pipeline assets such as TV-45070 and Nav1.6, among others. Some of these assets could be monetized through partnerships"
Phase II readouts for XEN801 for the treatment of acne is due out inthe first quarter of 2017 and a Phase II readout for TV-45070 against Postherpetic neuralgia should hit in the first half of 2017. The company has just a $125 million market capitalization, positive analyst support and a couple of definable upcoming catalysts. One has to like Xenon's risk/reward profile over the next few quarters.

Well, this is absolutely amazing! Opened at $9 literally a couple of days ago and now we're trading over $16 a share.